Organogenesis Holdings Inc. (ORGO) Stock Grade

About Organogenesis Holdings Inc.'s fundamentals

Organogenesis is a specialty pharmaceutical company with a market capitalization of $656.5 million that has demonstrated solid revenue growth of 16.8% year-over-year, indicating expanding business activity in its market segment. The company trades at a P/E ratio of 17.7 while maintaining a net profit margin of 6.6%, reflecting modest profitability on its revenue base. Return on equity stands at 8.5%, suggesting moderate efficiency in generating returns from shareholder capital, and the company does not currently pay a dividend.